The Alliance for Safe Biologic Medicines and other ASBM patient groups continue to write the Delaware House of Representatives requesting passage of Senate Substitute 1 for SB 118 regarding biosimilar products. A vote in the full House is expected Tuesday, May 13.
Letters to House of Representatives requesting final passage.
View AARDA letter here.
View ASBM letter here.
View GHLF letter here.
View RetireSafe letter here.
Letters to Delaware House Health and Human Development Committee:
View ASBM letter here.
View GHLF letter here.
View AARDA letter here.
View RetireSafe letter here.